Novo Nordisk drops 4.5% as 4th-qtr results miss estimates, cuts long-term profit view

3 February 2016

Shares in Danish insulin giant Novo Nordisk (NOV: N) fell nearly 4.5% in morning trade on the Copenhagen Stock Exchange after the company posted quarterly results below expectations and lowered its long-term profit outlook.

Results were also impacted by the slowdown in sales of diabetes drug Victoza (liraglutide injection), on the back of market competition.

Novo Nordisk said its long-term target for operating profit growth has now been set at 10%, down from 15% forecast earlier, but no target for operating margin development has been established, as the operating margin is expected to stay at its current level around 44%. For 2016, the company sees sales growth of 5%-9%. Operating profit is also expected grow 5%-9%, it said in a statement.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK